Innovent Starts China Trials of PD-1/PD-L1 Bispecific Antibody

Innovent Biologics (Suzhou) has dosed the first patient in a Phase I trial of a bispecific antibody that targets both PD-1 and PD-L1. According to Innovent, the candidate (IBI318) is the first PD-1/PDL1 bispecific to start clinical trials anywhere in the world. Innovent discovered and partnered IBI318 with Lilly as part of their $1 billion agreement, announced in 2015. The China Phase I trial will test the candidate for safety, tolerability and initial efficacy in patients with advanced malignancies. More details.... Stock Symbols: (HK: 01801) (NYSE: LLY) Share this with colleagues: // //